Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Arsenic trioxide — An old drug rediscovered

(2010) Ashkan Emadi et al.   BLOOD REVIEWS

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

PML Nuclear Bodies

(2010) V. Lallemand-Breitenbach et al.   Cold Spring Harbor Perspectives in Biology

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia

(2009) J. Zhou et al.   BLOOD

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

(2009) J. Hiraga et al.   BLOOD

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

(2008) M. A. Sanz et al.   BLOOD

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

(2008) Michael H. Tatham et al.   NATURE CELL BIOLOGY

Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

(2008) Valérie Lallemand-Breitenbach et al.   NATURE CELL BIOLOGY